ATE496901T1 - Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung - Google Patents

Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Info

Publication number: ATE496901T1
Authority: AT; Austria
Prior art keywords: production; tetrahydrocannabinol; delta; cannabinoid derivatives; cannabinoid
Prior art date: 2003-05-20

Application number

AT04752828T

Other languages

English (en)

Inventor

Bob Moore

Antonio Ferreira

Mathangi Krishnamurthy

Original Assignee

Univ Tennessee Res Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-20

Filing date

2004-05-20

Publication date

2011-02-15

2004-05-20 Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE496901T1 publication Critical patent/ATE496901T1/de

Links

229930003827 cannabinoid Natural products 0.000 title abstract 2
239000003557 cannabinoid Substances 0.000 title abstract 2
102000012234 Cannabinoid receptor type 1 Human genes 0.000 abstract 4
108050002726 Cannabinoid receptor type 1 Proteins 0.000 abstract 4
102000008906 Cannabinoid receptor type 2 Human genes 0.000 abstract 4
108050000860 Cannabinoid receptor type 2 Proteins 0.000 abstract 4
XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 abstract 1
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
229960004242 dronabinol Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

AT04752828T 2003-05-20 2004-05-20 Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung ATE496901T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47231603P	2003-05-20	2003-05-20
PCT/US2004/015885 WO2004113320A1 (en)	2003-05-20	2004-05-20	Cannabinoid derivatives, methods of making, and use thereof

Publications (1)

Publication Number	Publication Date
ATE496901T1 true ATE496901T1 (de)	2011-02-15

Family

ID=33539041

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752828T ATE496901T1 (de)	2003-05-20	2004-05-20	Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung

Country Status (10)

Country	Link
US (2)	US7169942B2 (de)
EP (1)	EP1633733B1 (de)
JP (1)	JP2007501279A (de)
CN (1)	CN1809552A (de)
AT (1)	ATE496901T1 (de)
AU (1)	AU2004249669B2 (de)
CA (1)	CA2526103A1 (de)
DE (1)	DE602004031221D1 (de)
DK (1)	DK1633733T3 (de)
WO (1)	WO2004113320A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005093052A1 (en) *	2004-03-26	2005-10-06	Fuji Photo Film Co., Ltd.	Method for selectively separating and purifying rna and method for separating and purifying nucleic acid
USRE46558E1 (en)	2005-04-28	2017-09-26	Paloma Pharmaceuticals, Inc.	Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US8475776B2 (en) *	2005-04-28	2013-07-02	Paloma Pharmaceuticals, Inc.	Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20060257337A1 (en) *	2005-04-28	2006-11-16	David Sherris	Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
EP2578561A1 (de)	2005-09-29	2013-04-10	Albany Molecular Research, Inc.	Verfahren zur Herstellung von Cannavbidiolderivaten und deren Intermediaten
DE102005062098A1 (de) *	2005-12-22	2007-06-28	Merck Patent Gmbh	Oxaphenanthren-Derivate
EP2131655B1 (de)	2007-03-02	2014-05-07	The University of Tennessee Research Foundation	Triaryl-/heteroaromatische cannabinoide und ihre verwendung
WO2009120799A2 (en) *	2008-03-25	2009-10-01	Paloma Pharmaceuticals, Inc.	Methods of treating fibrotic disorders
WO2009143182A1 (en) *	2008-05-19	2009-11-26	University Of Tennessee Research Foundation, The	Pyrimidine classical cannabinoid compounds and related methods of use
US8476439B2 (en)	2008-05-19	2013-07-02	The University Of Tennessee Research Foundation	Pyridine classical cannabinoid compounds and related methods of use
WO2009143183A1 (en) *	2008-05-19	2009-11-26	University Of Tennessee Research Foundation, The	Pyrimidine non-classical cannabinoid compounds and related methods of use
US8349876B2 (en) *	2008-05-19	2013-01-08	The University Of Tennesee Research Foundation	Pyridine non-classical cannabinoid compounds and related methods of use
JP2011520973A (ja) *	2008-05-19	2011-07-21	ユニヴァーシティオブテネシーリサーチファウンデーション，ザ	ピリジンの非古典的カンナビノイド化合物及び関連する使用方法
US8389534B2 (en) *	2008-05-19	2013-03-05	The University Of Tennessee Research Foundation	Pyrimidine non-classical cannabinoid compounds and related methods of use
JP2011520972A (ja) *	2008-05-19	2011-07-21	ユニヴァーシティオブテネシーリサーチファウンデーション，ザ	ピリジンの古典的カンナビノイド化合物及び関連する使用方法
EP2309858A4 (de)	2008-07-31	2011-09-14	Dekel Pharmaceuticals Ltd	Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
US9381187B2 (en)	2011-02-16	2016-07-05	Paloma Pharmaceuticals, Inc.	Radiation countermeasure agents
CN103110582A (zh) *	2013-03-04	2013-05-22	上海医药工业研究院	大麻酚类化合物微乳剂及其制备方法
EP3160445B1 (de)	2014-06-26	2021-10-20	Island Breeze Systems Ca, LLC	Mdi-verwandte produkte und verfahren zur verwendung
US20170008869A1 (en) *	2015-07-10	2017-01-12	Noramco, Inc.	Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
IL248149B (en) *	2016-09-29	2020-03-31	Garti Nissim	Dilutable formulations of cannbinoids and processes for their preparation
US10239808B1 (en)	2016-12-07	2019-03-26	Canopy Holdings, LLC	Cannabis extracts
US20180169061A1 (en) *	2016-12-15	2018-06-21	Ascent Pharmaceuticals, Inc.	Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
KR102652605B1 (ko) *	2017-08-27	2024-03-28	로드스 테크놀로지즈	안과 질환 치료를 위한 약학제적 조성물
US11202771B2 (en)	2018-01-31	2021-12-21	Treehouse Biotech, Inc.	Hemp powder
EP3840854A4 (de) *	2018-08-20	2022-06-29	Bessor Pharma, LLC	Neuartige cannabinoide und cannabinoidsäuren und deren derivate
EP3864000A4 (de)	2018-10-10	2022-08-10	Treehouse Biosciences, Inc.	Synthese von cannabigerol
CN110269839A (zh) *	2019-06-15	2019-09-24	云南飞久逍科技有限公司	一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
CN114727960A (zh) *	2019-10-03	2022-07-08	耶路撒冷希伯来大学伊森姆研究发展有限公司	数个脂质体大麻素及其用途
WO2021091908A1 (en)	2019-11-08	2021-05-14	Vella Bioscience, Inc.	Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941782A (en) *	1972-04-27	1976-03-02	Sharps Associates	Heterocyclic esters of benzopyrans
US3915996A (en) *	1972-10-16	1975-10-28	Abbott Lab	Process for making benzopyrans
US3901926A (en) *	1973-04-02	1975-08-26	Abbott Lab	Alkylphenyl benzopyrans
DE4100441A1 (de) *	1991-01-09	1992-07-16	Mack Chem Pharm	Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US5596106A (en) *	1994-07-15	1997-01-21	Eli Lilly And Company	Cannabinoid receptor antagonists
CA2278307A1 (en) *	1997-01-21	1998-07-23	Siegfried Benjamin Christensen Iv	Novel cannabinoid receptor modulators
FR2758723B1 (fr) *	1997-01-28	1999-04-23	Sanofi Sa	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) *	1997-02-21	1998-08-27	Bayer Ag	Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
EP0979228A4 (de) *	1997-03-18	2000-05-03	Smithkline Beecham Corp	Cannabinoid-rezeptor agonisten
US5939429A (en) *	1997-09-30	1999-08-17	Virginia Commonwealth University	Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) *	1998-05-04	1999-11-11	The University Of Connecticut	Novel analgesic and immunomodulatory cannabinoids
AU6088200A (en) *	1999-07-12	2001-01-30	Virginia Commonwealth University	Novel vasodilator cannabinoid analogs
FR2799124B1 (fr) *	1999-10-01	2004-08-13	Sanofi Synthelabo	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
IL132661A (en) *	1999-10-31	2008-11-26	Raphael Mechoulam	Agonists specific for peripheral cannabinoid receptors
FR2804604B1 (fr) *	2000-02-09	2005-05-27	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
JP2004502642A (ja) *	2000-02-11	2004-01-29	ブリストル−マイヤーズ　スクイブ　カンパニー	カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US20040039048A1 (en) *	2000-02-11	2004-02-26	Manuel Guzman Pastor	Therapy with cannabinoid compounds for the treatment of brain tumors
US6448288B1 (en) *	2000-05-17	2002-09-10	University Of Massachusetts	Cannabinoid drugs
CA2411585A1 (en) *	2000-06-22	2001-12-27	Pharmos Corporation	Novel non-psychotropic cannabinoids
US7067539B2 (en) *	2001-02-08	2006-06-27	Schering Corporation	Cannabinoid receptor ligands
US7507767B2 (en) *	2001-02-08	2009-03-24	Schering Corporation	Cannabinoid receptor ligands
US6509367B1 (en) *	2001-09-22	2003-01-21	Virginia Commonwealth University	Pyrazole cannabinoid agonist and antagonists
AR037352A1 (es) *	2001-11-14	2004-11-03	Schering Corp	Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos
EP1539693B9 (de) *	2002-06-19	2008-10-08	Schering Corporation	Agonisten des cannabinoidrezeptors
BR0314872A (pt) *	2002-10-18	2005-08-02	Pfizer Prod Inc	Ligandos do receptor canabinóide e usos dos mesmos

2004
- 2004-05-20 US US10/850,588 patent/US7169942B2/en not_active Expired - Fee Related
- 2004-05-20 JP JP2006533257A patent/JP2007501279A/ja active Pending
- 2004-05-20 CN CNA2004800174008A patent/CN1809552A/zh active Pending
- 2004-05-20 AT AT04752828T patent/ATE496901T1/de not_active IP Right Cessation
- 2004-05-20 EP EP04752828A patent/EP1633733B1/de not_active Expired - Lifetime
- 2004-05-20 DE DE602004031221T patent/DE602004031221D1/de not_active Expired - Lifetime
- 2004-05-20 WO PCT/US2004/015885 patent/WO2004113320A1/en not_active Ceased
- 2004-05-20 CA CA002526103A patent/CA2526103A1/en not_active Abandoned
- 2004-05-20 DK DK04752828.6T patent/DK1633733T3/da active
- 2004-05-20 AU AU2004249669A patent/AU2004249669B2/en not_active Ceased
2007
- 2007-01-26 US US11/698,665 patent/US20070167514A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040242593A1 (en)	2004-12-02
EP1633733B1 (de)	2011-01-26
CN1809552A (zh)	2006-07-26
WO2004113320A1 (en)	2004-12-29
AU2004249669B2 (en)	2008-05-22
US7169942B2 (en)	2007-01-30
DE602004031221D1 (de)	2011-03-10
EP1633733A1 (de)	2006-03-15
EP1633733A4 (de)	2007-02-28
DK1633733T3 (da)	2011-05-16
US20070167514A1 (en)	2007-07-19
AU2004249669A1 (en)	2004-12-29
CA2526103A1 (en)	2004-12-29
JP2007501279A (ja)	2007-01-25

Legal Events

Date	Code	Title	Description
2011-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004031221D1 (de)	2011-03-10	Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
CR6478A (es)	2004-02-02	Moduladores del receptor glucocorticoide
DE60120494D1 (de)	2006-07-20	Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
TR199801348T2 (xx)	1998-10-21	Heterosikl-kondanse morfinoid t�revleri(II).
DE69737592D1 (de)	2007-05-24	Mittel gegen juckreiz
DE60207514D1 (de)	2005-12-29	Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
EA199700156A1 (ru)	1997-12-30	Производные индола как антагонисты рецептора 5-нт
ATE272631T1 (de)	2004-08-15	Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
BR9914526A (pt)	2001-07-03	Derivados de adenina
TR200100267T2 (tr)	2001-09-21	İkameli anilid bileşimleri ve yöntemler.
PT1218352E (pt)	2004-09-30	Novos derivados de benzimidazolona tendo receptores com afinidade mista para os receptores de serotonina e dopamina
DE50106600D1 (de)	2005-07-28	Verwendung von hydrophil modifizierten polyisocyanaten und polyurethanen als antiknitteradditiv für den heimbereich
DK1019426T3 (da)	2003-07-14	Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
ATE473294T1 (de)	2010-07-15	Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
ATE239823T1 (de)	2003-05-15	Verffahren und vorrichtung zur steuerung der papiereigenschaften
HUP0100621A2 (hu)	2001-08-28	Monoamin oxidáz inhibitor hatású vegyületek és h5-HT1B antagonista vagy részleges agonista hatású vegyületek kombinációját tartalmazó gyógyászati készítmények
AU5614198A (en)	1998-07-15	Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
DE50000767D1 (de)	2002-12-19	Mit nanopartikeln modifizierte bindemittel für überzugsmittel und deren verwendung
TR199700956T1 (xx)	1998-02-21	Indazolkarboksamidler.
DE60103856D1 (de)	2004-07-22	Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
BR0307903A (pt)	2006-04-04	derivados de arilsulfona
EP1305023A4 (de)	2005-02-23	Verwendung selektiver agonisten, antagonisten und allosterischer verstärker des adenosin-a1-rezeptors zur beeinflussung der angiogenese
DE69633131D1 (de)	2004-09-16	Rezeptor des y-y5 neuropeptids
DE50209113D1 (de)	2007-02-08	1-allyl-ergotalkaloid-derivate- verfahren zu ihrer herstellung und ihre verwendung zur prophylaxe und therapie von migräne